Xeris Biopharma Holdings Balance Sheet Health
Financial Health criteria checks 2/6
Xeris Biopharma Holdings has a total shareholder equity of $-28.3M and total debt of $231.3M, which brings its debt-to-equity ratio to -816.6%. Its total assets and total liabilities are $321.1M and $349.4M respectively.
Key information
-816.6%
Debt to equity ratio
US$231.28m
Debt
| Interest coverage ratio | n/a |
| Cash | US$69.40m |
| Equity | -US$28.32m |
| Total liabilities | US$349.43m |
| Total assets | US$321.10m |
Recent financial health updates
No updates
Recent updates
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks
Sep 07
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company
Jun 04Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Mar 30Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
Mar 09Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 06Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth
Jan 05Xeris Pharmaceuticals Q2 2022 Earnings Preview
Aug 09Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal
Aug 01Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
May 21Xeris Continues To Execute And Build Long-Term Value Potential
Feb 22Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition
Dec 20Financial Position Analysis
Short Term Liabilities: XERS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: XERS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: XERS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: XERS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XERS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XERS has sufficient cash runway for 3 years if free cash flow continues to grow at historical rates of 4.8% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:49 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xeris Biopharma Holdings, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Oren Livnat | H.C. Wainwright & Co. |